OLN Earnings Recap
Beat 5 of last 7 quarters
The Buildout is a website built on agentic AI tools, currently in beta, and could have factual errors.
Olin's results reflect the ongoing impact of geopolitical disruptions on chemical supply chains, with pricing spikes and cost inflation affecting the broader industrial complex. The company's focus on structural cost reduction and the planned Huntsman merger position it to benefit from a tighter chlor-alkali market, which is a key input for many downstream industries. The use of AI and digital tools to improve reliability and reduce costs is a signal of broader efficiency trends in the chemicals sector.
Q2 saw the conflict involving Frank disrupt chemical supply chains and increase prices, with caustic soda and EDC export pricing benefiting, partially offset by an unplanned VCM shutdown at Freeport. Epoxy posted its best results in over three years, returning to positive earnings. Winchester commercial demand improved year-over-year, with pricing initiatives offsetting higher metals costs. The company announced a planned merger with Huntsman, filed the definitive proxy on July 13, and expects to close in the first half of 2027.
Management expects Q3 Chemicals adjusted EBITDA to be relatively flat sequentially, with overall adjusted EBITDA in the $100M-$200M range. Domestic caustic pricing is expected to strengthen, while export volumes improve but are offset by lower pricing. Epoxy volumes and mix should improve, but higher European FIFO costs will be a headwind. Winchester is expected to improve on higher commercial volumes and pricing, partially offset by higher metals costs. The company reaffirmed its Beyond250 target of $250M in structural savings by 2028, with confidence to exceed it, and expects to deliver over $100M in incremental savings in 2026. The Huntsman merger is on track to close in the first half of 2027, with $400M in synergies expected.
“On June 16, we were very pleased to announce our planned merger with Huntsman. Bringing together 2 highly complementary businesses, to create a world scale vertically integrated North American focused chemical leader with more than $12 billion in sales.”
on Huntsman merger
“We expect product availability to tighten in the fourth quarter driven by persistently higher feedstock and energy costs as well as several planned industry shutdowns.”
on Supply outlook
“We are increasingly confident that we will exceed our $250 million target by 2028.”
on Beyond250 cost savings
Where has the Frank conflict had the biggest impact within Olin, and what are the implications if it drags on?
The biggest impact was in Q2 with price spikes and supply disruption concerns, which have since abated. Going forward, higher global costs, especially for non-US producers, should put a higher floor under prices. Export pricing softness in Q3 is due to digesting volumes produced during the spike, but supply should tighten in Q4.
How do you view near-term supply/demand dynamics for chlorovinyls, including Middle East capacity return, European rationalization, and potential restocking in Asia?
Q2 saw a spike in operating rates, but those have reversed. Middle East capacity return is less of a concern; the key is China's operating rates, which have already been reduced. European operating rates have come back down. Customer destocking could lead to a restocking cycle, but underlying demand remains stable, not recovering.
Can you walk through the building blocks to the 4.5x year-end leverage target?
Net debt will increase year-over-year due to ~$195M of legacy litigation payments. Trailing twelve-month adjusted EBITDA is ~$5.7B, and Olin generated ~$100M of levered free cash flow even at those levels, after dividends, capex, and interest.